**Mina LuQing Xu**

minaxu@post.harvard.edu

8/2017 - present **Yale-New Haven Hospital/Yale School of Medicine**

 *Director of Hematopathology (2016-present)*

 *Associate Professor of Pathology and Laboratory Medicine*

8/2011 - 2016 **Yale-New Haven Hospital/Yale School of Medicine**

 *Assistant Professor of Pathology and Laboratory Medicine*

**Education:**

7/2010 - 6/2011 **Brigham and Women’s Hospital/Harvard Medical School**

 *Hematopathology Fellow*

7/2006 - 6/2010 **Yale-New Haven Hospital/Yale School of Medicine**

*Anatomical and Clinical Pathology Resident*

 *Chief Resident*, 2009 – 2010

9/2001 - 6/2006 **UCSF School of Medicine**, *M.D.*

 *American Society of Hematology Trainee*, 2004 – 2005

9/1996 - 6/2000 **Harvard University**, *A.B. with Honors in Biology*

**Career/Academic Appointments:**

2004 - 2005 Research Fellow, Dr. John Aster, Hematopathology, Brigham and Women’s Hospital

2006 - 2009 Resident and Chief Resident, Anatomical and Clinical Pathology, Yale-New Haven Hospital, New Haven, CT

2010 - 2011 Postdoctoral Fellow in Hematopathology, Brigham and Women’s Hospital, Harvard Medical School

2011 - 2017 Assistant Professor, Dept. of Pathology and Dept. of Laboratory Medicine, Yale University School of Medicine, Yale-New Haven Hospital New Haven, CT

2017 - present Associate Professor, Dept. of Pathology and Dept. of Laboratory Medicine, Yale University School of Medicine, Yale-New Haven Hospital New Haven, CT

**Administrative Positions:**

2016 - present Director of Hematopathology, Yale University School of Medicine

2015 - 2016 Associate Director of Hematopathology, Yale University School of Medicine

2016 - present PI of Lymphoma Biobank, Yale Pathology

2017 - present Course Director, Hematopathology for 1st year medical students, Yale School of Medicine

**Board Certification:**

2010 American Board of Pathology, Anatomic and Clinical Pathology

2011 American College of Pathology, Hematopathology

**Professional Honors & Recognition**

**International/National/Regional**

2005 American Society of Hematology Trainee Grant

1996 Weizmann Institute of Science Scholarship

1995 Westinghouse Semifinalist

1995 National Merit Finalist

1994 Junior NSF Grant

**University**

2019 Yale Pathology Retreat Research Pitch Contest Winner

2007 Dr. Halina Goldstein Award for Outstanding Achievement in Autopsy Pathology

2000 Elizabeth Cary Agassiz Certificate of Merit for Academic Achievement

1996 - 2000 Harvard University Dean’s List

1996 Rotary Scholarship

**Grant/Clinical Trials History:**

**Current Grants**

Agency: NIH
I.D.# U54AG076043-01
Title: “Yale TMC for cellular senescence in lymphoid organs” SenNet Center Grant
PI: Rong Fan, PhD
Co-PI of Biospecimen core; Percent effort: 5% effort
Total costs for project period: $6,500,000
Project period: 09/30/21-8/31/26

Agency: NIH
I.D.# U01CA260507-01
Title: “Immunoserological assays for COVID19 management in patients with hematological malignancies”
PI: Rong Fan, PhD
Co-I Percent effort: 5% effort
Total costs for project period: $500,000
Project period: 09/30/20 – 09/30/25

**Past Grants**

Agency: NIH
I.D.# 1R21AI154187-01
Title: “Human B cell infiltration into allografts: mechanisms and molecules”
PI: Jordan Pober, MD, PhD
Co-PI Percent effort: 5%
Total costs for project period: $150,000
Project period: 07/01/20 – 06/30/22

Agency: DeLuca Fund

I.D.# Private donor

Title: “Immunophenotypic and functional assessments of human tumor vessels in the lymphoma microenvironment and tumor susceptibility to CAR-T therapy”

PI. Iris Isufi, MD

Co-PI Percent effort: no salary support

Total costs for project period: $50,000

Project period: 09/01/20-09/01/22

Agency: DeLuca Fund

I.D.# Private donor

Title: “Defining clonal heterogeneity and disease risk by targeted biopsies during treatment of multiple myeloma”

PI Natalia Neparidze, MD

Co-I Percent effort: no salary support

Total costs for project period: $100,000

Project period: 01/01/20-01/01/21

Agency: Boehringer Ingelheim Pharmaceuticals, Inc

I.D.# Clinical Trial

Title: “A Phase I-II randomized trial of a combination of Nintedanib/Placebo in combination with induction chemotherapy for patients with refractory or first relapse Acute Myeloid Leukemia”

PI: Thomas Prebet, MD, PhD

Co-I Percent effort: 5%

Total costs for project period: $497,219

Project period: 06/05/16 – 06/14/18

Agency: Yale Pathology
I.D.# Chairman’s Challenge Award
Title: “Vascular phenotyping and functional analysis in human B-cell lymphomas”
PI: Mina Xu, MD
PI Percent effort: no salary support

Total costs for project period: $10,000
Project period: 10/12/2018 – 10/12/2020

Agency: Leukemia Research Foundation
I.D.# New Investigator Grant
Title: “Genetic and environmental contributions to Mantle Cell Lymphoma Pathogenesis”
PI: Samuel Katz, MD, PhD
Co-I Percent effort: 5%
Total costs for project period: $100,000
Project period: 07/01/2014 – 12/31/2015

Agency: Yale Pathology
I.D.# Chairman’s Challenge Award
Title: “Immunohistochemical translation of genetic findings of whole exome sequencing”
PI: Mina Xu, MD
PI Percent effort: no salary support

Total costs for project period: $10,000
Project period: 01/01/2014 – 01/01/15

Agency: Gilead Foundation
I.D.# Yale Center for Genome Analysis
Title: “Peripheral T-cell Lymphoma NOS”
PI: Mina Xu, MD
PI Percent effort: no salary support
Total costs for project period: $100,000
Project period: 06/15/2012 – 06/19/2014

Agency: St. Baldrick’s Foundation

I.D.# Infrastructure Grant

Title: “Identifying candidate genes involved in familial Hodgkin lymphoma”

PI: Gary Kupfer, MD, PhD

Co-I Percent effort: no salary support

Total costs for project period: $50,000

Project period: 01/01/2010 — 06/30/2011

**Scheduled Invited Speaking Engagements, Presentations, Symposia & Workshops:**

2023 MDS Workshop Presentation, Dubrovnik, Croatia

2023 Grand Rounds at Houston Methodist Hospital/Weill Medical College of Cornell University, TBA, Houston, TX

2023 Grand Rounds at Memorial Sloan Kettering Cancer Center, New York, NY

2023 Invited Speaker for CAP Hot Topics Lecture, CAP Annual Meeting

**Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale:**

**International/National**

2023 USCAP Short Course “Roadmap to cytoses: Guide to navigating the elevated blood count” New Orleans, LA

2023 HemeReports: ASH22 Classification and Surveillance of Myeloid Diseases. Online Webinar

2022 International Workshop on Myelodysplastic Syndromes (iwMDS) for Clinical Oncologists/Hematologists: Expert Pathology Presenter for MDS Morphology Workshop “Mimics of MDS” Miami, FL

2022 Diagnostic Pathology CME “Diagnosing lymphoma on ever smaller needle biopsies” New York City, NY

2022 USCAP Short Course “Roadmap to cytoses: Guide to navigating the elevated blood count” Los Angeles, CA

2021 Grand Rounds: “IRF8 in monocytic leukemias: discovering a novel monoblast biomarker” UCLA, Los Angeles, CA

2021 Update in Hematopathology Faculty for Hawaii Hemepath Conference (Pathology Education Partners CME Series) Maui, HI:

 “Myeloproliferative neoplasms and mimics”

 “Practical approach to myelodysplastic syndrome: tackling big data integration”

 “Defining the boundaries between classic Hodgkin lymphoma, primary mediastinal lymphoma and mediastinal gray zone lymphoma”

 “Getting to correct: diagnosing lymphomas on ever smaller needle biopsies”

2021 National Lymphoma Rounds (Lymphoma Research Foundation) Presenter & Panelist: “Peripheral T-cell Lymphoma with Cutaneous Presentation” Virtual

2021 Pathology Department Speaker Series: “T-cell lymphoma update” Brown University, RI

2021 New York Lymphoma Rounds (Lymphoma Research Foundation) Presenter & Panelist: “T-cell Lymphoma” Virtual

2021 Lymphoma Research Foundation Virtual Lymphoma Rounds Panelist: “Challenging T-cell lymphoma diagnoses in the bone marrow” Virtual

2019 Grand Rounds: “From Mouse to Microscope: Biomarker discovery in Mantle Cell Lymphoma” Dalhousie University, Halifax, CANADA

2019 Advanced Science Workshop on Myeloid Malignancies: “Diagnostic and WHO Classification of Myeloid Malignancies” New Haven, CT

2019 USCAP Interactive Microscopy Course Faculty: “Terrible T-cell Tumors: focus on updates to the WHO” Washington, DC

2018 Grand Rounds: “Troubling T-cell tumors: genetic update on PTCL, NOS,” Peking University; Beijing Cancer Hospital, Beijing, CHINA

2018 Workshop on T-cell lymphoma Diagnosis and Subclassification, Peking University; Beijing Cancer Hospital, Beijing, CHINA

2018 Chinese American Pathologists Association (CAPA) Online Education Program: Hematopathology presentation

2018 USCAP Interactive Microscopy Course Faculty: “Terrible T-cell Tumors: focus on updates to the WHO” Vancouver, CA

2017 Pathology Update Course: “Molecular diagnostics in T-cell Lymphomas,” College of American Pathologists, Washington, DC

2017 Grand Rounds: “T-cell Dumpster Diving: discovering genetic abnormalities in Peripheral T-cell Lymphoma, NOS,” NYU, NY

2017 Hematopathology Case Conference Tutorial for Residents, NYU, NY

2016 Grand Rounds: “Emptying the wastebasket: Finding genetic aberrations in Peripheral T-cell Lymphomas, NOS,” Cornell University, NY

2016 Pathology Update Course: “Molecular diagnostics in T-cell Lymphomas,” Ohio State University, OH

2016 Grand Rounds: “Emptying the wastebasket: Finding genetic aberrations in Peripheral T-cell Lymphomas, NOS,” University of Michigan, MI

2015 “Overview of Peripheral T-cell Lymphomas and their Molecular Landscape,” New York Oncology Hematology, Albany, NY

2010 Grand Rounds: “Molecular Pathophysiology: T lymphoblastic leukemia,” University of Rochester, NY

2008 Hematopathology research talk: “A tail of notch in T lymphoblastic leukemia,” NIH, MD

**Regional**

2022 Yale Hematology/Oncology Research Seminar: “Discovering a Monoblast Marker” New Haven, CT

2017 Yale Therapeutic Radiology Grand Rounds: “Jewels in the Wastebasket: Molecular Findings in Peripheral T-cell Lymphoma, NOS” New Haven, CT

2016 “Molecular diagnostics in T-cell Lymphomas,” Science of Lymphoma and Associated Receptors, Hartford, CT

2016 “Molecular diagnostics in T-cell Lymphomas,” Science of Lymphoma and Associated Receptors, Fairfield, CT

2016 “Molecular diagnostics in T-cell Lymphomas,” Science of Lymphoma and Associated Receptors, Danbury Hospital, CT

2013 “Role of Plasmacytoid Dendritic Cells in Myeloid Neoplasms,” Connecticut Society for Hematopathology, New Haven, CT

**Intradepartmental**

2022 Yale Pathology Grand Rounds: “Discovering a Monoblast Marker” New Haven, CT

2020 Yale Pathology Grand Rounds: “From Mouse to Microscope: Biomarker discovery in Mantle Cell Lymphoma” New Haven, CT

**Peer-Reviewed Presentations & Symposia**

**International/National**

2023 Wong J, Roy S, McNiff J, **Xu ML**. IRF8 is a plasmacytoid dendritic cell marker that can differentiate subcutaneous panniculitis-like T-cell lymphoma from lupus erythematosus panniculitis. USCAP platform presentation, New Orleans, LA.

2023 **Xu ML**, Thakkar D, ABCG Consortium, Dave SS. Mutations in ASXL1 and/or TET2 identify a subset with worse outcomes in patients with blastic plasmacytoid dendritic cell neoplasms. USCAP platform presentation, New Orleans, LA.

2022Mata DA, Lee JK, Decker B, Shanmugam V, Marcus CB, Tukachinsky H, Schrock AB, Patel NR, Ross JS, Oxnard GR, Vergilio J, Mirza KM, Benhamida JK, **Xu ML**. Liquid biopsy-based next generation sequencing is an alternative to tissue molecular profiling of lymphoid, plasma cell and myeloid neoplasms. Oral presentation at American Society of Hematology, New Orleans, LA.

2022 Chapman J, Thakkar D, Alderuccio J, Kikkeri N, Ondrejka S, Hsi E, **Xu ML**, Paulson N, Koff J, Jaye D, Cohen J, Norgaard P, Breinholt M, Leeman-Neill R, Evans A, Behdad A, Galvez C, Czader M, Jiong Y, Dave S, Lossos I. Extranodal Marginal Zone Lymphomas show recurrent mutations in DNA repair genes, Cancer-associated proliferative signaling and NOTCH1 signaling pathways, regardless of anatomic site. Poster presentation at ASH, New Orleans, LA.

2022 Epperla N, Zaya A, Daniel L, Hughes M, Ayers E, Bock A, Nowakowski G, Mark G, Beckman A, Medeiros J, Kothari S, **Xu ML**, Torka P, Smith S, Kikkeri N, Bond, D, Saad M, Pandya K, Naik S, Kamdar M, Rubinstein P, Chaudhry A, Vose J, Nutsch H, Olszewski A. High-grade B-cell Lymphoma, not otherwise specified: central nervous system involvement, prophylaxis and recurrence risk in a multi-institutional series. Poster presentation at ASH, New Orleans, LA.

2022 Liu Y, Parker TL, Bar N, Dhodapkar M, Seropian S, **Xu ML**, Syam R, Gorshein E, Talsania A, Montanari F, Wei W, Haims A, Neparidze N. Enhanced global disease assessment with advanced imaging and targeted myeloma lesion biopsy highlights spatial heterogeneity and detects residual disease in multiple myeloma. Poster presentation at ASH, New Orleans, LA.

2022 Kalashnikov I, Karjalainen-Lindsberg M, Kovanen P, Dunkel J, Pasanen A, Kositsky R, Ondrejka SL, Hsi E, Evans A, Gang A, Czader M, Zhou J, **Xu ML**, Natkunam Y, Louissaint A, McCall C, Younes S, Chapman J, Amador C, Fedoriw Y, Chadburn A, Sojitra P, Behdad A, Naresh KN, Yin C, Goswami , Juskevicius R, Dave S. Nodular lymphocyte predominant Hodgkin lymphoma with splenic involvement is characterized by inflamed tumor microenvironment, high expression of checkpoint molecular gene-signature and adverse outcome. Poster presentation at ASH, New Orleans, LA.

2022 Liu Y, Parker TL, Bar N, Dhodapkar M, Seropian S, **Xu ML**, Witt D, Lischuk A, Chang V, Gorshein E, Talsania A, Montanari F, Wei W, Haims A, Neparidze N. Genomic sequencing of paired bone marrow and focal lesion biopsies of newly diagnosed multiple myeloma patients before and after induction therapy. Poster presentation at ASH, New Orleans, LA.

2022 Hrones M, Siddon A, Perincheri S, Foss F, **Xu ML**. Mature T-cell lymphomas with T-LBL characteristics. Poster presentation at CAP, New Orleans, LA.

2022 Mata DA, **Xu ML**, Shanmugam V, Tukachinsky H, Schrock AB, Ross JS, Williams A, Montesion M, Decker BJ, Vergilio J, Oxnard GR, Benhamida JK. Liquid-biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) for the evaluation of patients with myeloid neoplasms. Poster presentation at ASCO Annual Meeting, Chicago, IL.

2022 McQuaid D, Gauri P, Wang W, Katz SG, **Xu ML**. Global Assessment of IRF8 as a Novel Cancer Biomarker. Poster presentation at USCAP, Los Angeles, CA.

2022 McQuaid D, Katz SG, **Xu ML**. Novel Marker IRF8 Helps Differentiate Between CD30-Positive Large Cell Lymphomas. Poster presentation at USCAP, Los Angeles, CA.

2021 Zayac A, Arnason J, Sarit A, Balendra J, Bock A, Bond D, Bower M, Kamdar M, Yasmin K, Cerny, J, Issac D, Jagadeesh D, Kenkre V, Ollila T, Feldman T, El-Galaly TC, Bachanova V, Vose J, Evens A, Di M, Amitkumar M, **Xu ML**, Klein A, Lunning M, Phillips T, Kim S, Smith S, Sprague J, Alderuccio J, Olszewski A. High-grade B-cell lymphoma, not otherwise specified (HGBL, NOS): characteristics, treatment and outcomes from a multi-institutional series. Podium presentation at American Society of Hematology, Atlanta, GA.

2021 Love C, Pillai R, Ondrejka S, Bhagat G, Chadburn A, McKinney M, Koff J, Soliman D, Czader M, Louissant A, Li S, Ong C, Behdad A, Evens A, Natkunam Y, Chapman J, Fedoriw Y, Evans A, Goswami R, **Xu ML,** Naresh KN, Xiong B, Snowden A, Dave T, Thakkar D, Roth C, Dave S. The Atlas of Blood Cancer Genomes (ABCG) Project: A comprehensive molecular characterization of leukemias and lymphomas. Poster presentation at American Society of Hematology, Atlanta, GA.

2021 Matsumoto N, Ahmed A, Katz SG, Cohen P, **Xu ML**. The differential diagnosis of human herpesvirus type 8-associated large B-cell lymphomas. Presentation at SH/EAHP (Virtual)

2021 Ahmed A, **Xu ML**. Bone Marrow Workup: adult myelofibrotic myeloid neoplasms. Summary case presentation at SH/EAHP (Virtual)

2021 Li P, Biancon G, Patel T, Pan Z, Kothari S, Prebet T, Halene S, **Xu ML**. Clinicopathologic and comprehensive molecular analysis of mast cell leukemia with associated hematologic neoplasm. Poster presentation at USCAP (Virtual)

2021 Gisriel SD, **Xu ML**. Alpha-6 integrin and CNS metastasis of chemoresistant diffuse large B-cell lymphoma. Poster presentation at USCAP (Virtual)

2021 Hu Z, **Xu ML**, Yuan J, Peker D, Shao L, Rios A, Medeiros LJ, Hu S. T-Cell Prolymphocytic Leukemia (T-PLL) with t(X;14)(q28; q11.2): A Report of 17. Cases Poster presentation at USCAP (Virtual)

2021 Gisriel SD, Yuan J, Chen X, Wu X, McCracken J, Chen M, Paulson N, Wang E, **Xu ML**, Pan Z. Human herpesvirus 8 (HHV8)-negative effusion-based large B-cell lymphoma: a multicenter clinicopathologic study of 42 cases and review of the literature. Poster presentation at USCAP (Virtual)

2021 Gisriel SD, Yuan J, Chen X, Wu X, McCracken J, Chen M, Paulson N, Wang E, **Xu ML**, Pan Z. Diffuse large B-cell lymphoma with concurrent or subsequent lymphomatous effusion is associated with frequent MYC gene rearrangement and dismal prognosis. Poster presentation at USCAP (Virtual)

2020 Browning S, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Lee A, Prebet T, Gorshein E, Talsania A, Kidwai W, **Xu ML**, Chang V, Haims A, Neparidze N. Advanced imaging and targeted myeloma lesion biopsies to enhance global response assessment and evaluate spatial heterogeneity in multiple myeloma. Poster presentation at American Society of Hematology, San Diego, CA (Virtual)

2020 Kumar D, **Xu ML**. EBV-positive T-NK lymphoproliferative disorders with gamma/delta T-cell receptor expression. Oral presentation at New York Hematopathology Group Conference, New York, NY. (Virtual)

2020 Gu S, **Xu ML**, Pan Z. Pure extranodal presentation of primary effusion lymphomas. The twilight zone in myeloid neoplasms. Oral presentation at New York Hematopathology Group Conference, New York, NY. (Virtual)

2020 Ahmed A, Nguyen D, **Xu ML**. Risk of CNS progression in diffuse large B-cell lymphoma: site-specificity and mechanism of action. Poster presentation at USCAP, Los Angeles, CA.

2020 Paulson N, Pober J, **Xu ML**. Quantitative microvascular phenotyping of human B-cell lymphomas. Poster presentation at USCAP, Los Angeles, CA.

2020 Matsumoto N, Wang J, Shen Q, Chen X, Kim Y, Zuppan C, Chang C, **Xu ML**, Pan Z. Mast cell sarcoma: report of 5 cases with review of the literature. Poster presentation at USCAP, Los Angeles, CA.

2020 Weinberg O, Chisholm K, Ok C, Fedoriw Y, Mason E, Moser K, Bhattacharya S, **Xu ML**, Bagg A, George T, Wang S, Arber D, Hasserjian R. Clinical, immunophenotypic and genomic findings of NK-lymphoblastic leukemia. Poster presentation at USCAP, Los Angeles, CA.

2020 Ahmed F, Yuan J, Li P, **Xu ML**, Rimm D, Pan Z. Assessment of Ki67 proliferation index in mantle cell lymphoma with digital image analysis. Poster presentation at USCAP, Los Angeles, CA.

2020 Li, P, Yuan J, Ahmed F, Fu K, **Xu ML**, Rimm D, Pan Z. High counts of CD68+ and CD163+ macrophages in mantle cell lymphoma are associated with inferior prognosis. Poster presentation at USCAP, Los Angeles, CA.

2019 Chandhok NS, Huntington S, Isufi I, Gowda L, **Xu ML**, Bar N, Seropian S, Foss F. Peripheral blood involvement by flow cytometry as a prognostic factor in aggressive T-cell lymphomas following autologous stem cell transplantation. Poster presentation at American Society of Hematology, Orlando, FL.

2019 Ma J, Nie J, Inghirami G, Eng K, Elemento O, Au-Yeung R, Shen Y, Srivastava G, Gong J, **Xu ML**, Tan LH, Tam W. Heterogeneous genetic alterations and novel pathogenic pathways in relapsed DLBCL revealed by whole exome sequencing. Poster presentation at American Society of Hematology, Orlando, FL.

2019 Ahmed A, **Xu ML**. The twilight zone in myeloid neoplasms. Oral presentation at New York Hematopathology Group Conference, New York, NY.

2019 Maracaja D, Puthenpura V, Pels S, O’Malley D, Sklar J, Finberg K, **Xu ML**. EBV-positive primary large B-cell lymphoma: highlighting the role of XPO1 mutation in the diagnosis of mediastinal lymphomas. Poster presentation at American Society of Clinical Pathology (ASCP) Annual Meeting; Phoenix, AZ.

2019 Maracaja D, **Xu ML**. In the ring with systemic mastocytosis: a case of quickly evolving eosinophilia. Summary case presentation at SH/EAHP, Phoenix, AZ.

2019 Paulson N, **Xu ML**. Wrestling with mast cells in PDGFRA: who’s the heavyweight? Summary case presentation at SH/EAHP, Phoenix, AZ.

2019 Irshaid L, Weinberger E, Garritano J, Patsenker J, Kluger Y, Katz SG, **Xu ML**. Histopathologic and machine deep learning criteria to predict lymphoma transformation in bone marrow biopsies. Poster presentation at USCAP, Washington, DC.

2019 Patel SS, Ho C, Sadign S, Bagg A, Geyer J, **Xu ML**, Mason EF, Morgan EA, Steensma DP, Winer E, Hasserjian R, Weinberg O. Clinicopathologic and genetic characterization of non-AML NPM1-mutated myeloid neoplasms. Oral presentation at USCAP, Washington, DC.

2019 Gong, Z, Chen M, **Xu ML**, Cui W, Zhou T, Wang W, Medeiros J, Hu S. Philadelphia chromosome-negative “blast phase” of chronic myeloid leukemia. Poster presentation at USCAP, Washington, DC.

2019 Wang J, Katz SG, Morgan EA, Yang DT, Pan X, **Xu ML**. Pro-apoptotic BIM as a prognostic factor in mantle cell lymphoma. Poster presentation at USCAP, Washington, DC.

2019 Matsumoto NP, **Xu ML**, Gibson J. Paucity of plasma cells in the gut in patients following stem cell transplantation. Poster presentation at USCAP, Washington, DC.

2019 Chen P, O’Malley D, **Xu ML**. Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx. Poster presentation at USCAP, Washington, DC.

2019 Panse G, **Xu ML**. Cutaneous involvement by multiple myeloma. Oral presentation at International Society of Dermatopathology, Washington, DC.

2018 Wang J, Katz S, Morgan E, Yang D, Pan X, **Xu ML**. Pro-apoptotic protein BIM as a prognostic factor in mantle cell lymphoma. Oral presentation at New York Hematopathology Group Conference, New York, NY.

2018 Maracaja D, Puthenpura V, Pels S, O’Malley D, Finberg K, Sklar J, **Xu ML**. Exportin some help: the role of XPO1 mutation in the diagnosis of EBV positive primary mediastinal large B-cell lymphoma. Oral presentation at New York Hematopathology Group Conference, New York, NY.

2018 Chen P, Yang Y, O’Malley D, **Xu ML**. Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx. Poster presentation at EAHP, Edinburgh, Scotland.

2018 Kumar D, Toki M, Rimm D, **Xu ML**. Benign lymph node microenvironment is associated with response to immunotherapy. Poster presentation at USCAP, Vancouver, Canada.

2018 Chandler J, **Xu ML**, Hui P, Cai G. Diagnosis of lymphoproliferative disorders on CSF specimens-the utility of gene rearrangements in conjunction with cytologic evaluation. Poster presentation at USCAP, Vancouver, Canada.

2017 Kim T, Wang J, Sanmamed M, Zhang T, Halene S, Pillai M, Lu J, **Xu ML**, Zeidan A, Gore S, Dhodapkar M, Chen L. PD-1H (VISTA) induces immune evasion in acute myeloid leukemia. Poster presentation at American Society of Hematology, Atlanta, GA.

2017 Bailur JK, Mehta S, Zhang L, Neparidze N, Parker TL, Bar N, Anderson T, **Xu ML**, Dhodapkar K, Dhodapkar M. Early enrichment and subsequent dysfunction of marrow ILC subsets in monoclonal gammopathy: target for IMiD Therapy. Poster presentation at American Society of Hematology, Atlanta, GA.

2017 **Xu ML**. Genetics revealing the biology of acute leukemias: lymphoid and myeloid neoplasms with shared genetic abnormalities over time. Summary case presentation at SH/EAHP, Chicago, IL.

2017 Katz S, **Xu ML**. Genetic testing in the diagnosis of acute leukemias: sequencing for myeloid mutations in undifferentiated leukemias. Summary case presentation at SH/EAHP, Chicago, IL.

2017 Baraban E, Hu S, Hui P, Cooper D, Podoltsev N, **Xu ML**. Tissue based chimerism analysis enhances detection of donor derived neoplasia in allogeneic stem cell transplant patients. Poster presentation at USCAP, San Antonio, TX.

2017 Pelland K, Mathews S, Kamath A, Cohen PJ, Hudnall D, **Xu ML**. Dendritic markers aid in distinguishing mediastinal gray zone lymphoma from Classical Hodgkin Lymphoma and Primary Mediasinal Large B-cell Lymphoma. Poster presentation at USCAP, San Antonio, TX.

2016 Perincheri S, Goh G, Foss F, Lifton R, **Xu ML**. Loss of a novel tumor suppressor KLF9 identifies a subset of peripheral T-cell lymphomas, NOS with increased NOTCH1 expression. Poster presentation at USCAP, Seattle, WA.

2016 Ross J, **Xu ML**, Hui P, Humphrey PA, Adeniran A. Lymphomas of the urinary tract and genital organs: an institutional study of 50 cases. Poster presentation at USCAP, Seattle, WA.

2015 Verma R, Mai Z, **Xu ML**, Zhang L, Dhodapkar K, Dhodapkar M. Identification of a cereblon-independent protein degradation pathway in residual myeloma cells treated with immunomodulatory drugs. Oral presentation at American Society of Hematology, Orlando, FL.

2015 Song Y, Taylor A, Rongvaux A, Jiang T, Podolstev N, **Xu ML**, Neparidze N, Torres R, Barbarotta L, Balasubramanian K, Finberg K, Kluger Y, Flavell R, Halene S. Efficient engraftment and disease replication of myelodysplastic syndromes using a novel humanized mice model. Poster presentation at American Society of Hematology, Orlando, FL.

2015 Carey C, Gusenleitner D, Zhang X, Sohani A, Weinberg O, **Xu ML**, Yu H, Chen B, Woda B, Fu K, Monti S, Rodig S. Resolving the biological heterogeneity of B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL (BCL-U) using quantitative profiles of oncogenic signaling networks. Poster presentation at American Society of Hematology, Orlando, FL.

2015 **Xu ML**. Lymphoproliferative disorders and mimics associated with primary (congenital) immunodeficiency: hysterectomy in a CVID patient. Case Presentation. Society for Haematopathology/European Association for Haematopathology Annual Workshop, Long Beach, CA.

2015 Song Y, Rongvaux A, Taylor A, Podoltsev N, **Xu ML**, Neparidze N, Torres R, Barbarotta L, Balasubramanian K, Finberg K, Flavell R, Halene S. Humanized mice afford efficient engraftment and disease replication of myelodysplastic syndromes. Oral presentation at International Symposium on Myelodysplastic Syndromes, Washington, DC.

2015 **Xu ML**, Acevedo-Gadea C, Seropian S, Katz S. CD30 Expression does not predict response to brentuximab vedotin. Poster presentation at USCAP, Boston, MA.

2015 **Xu ML**, Gibson J. Plasma cell paucity in the gut following stem cell transplant. Poster presentation at USCAP, Boston, MA.

2014 Fraser, J, Subtil A, Alpdogan O, Seropian S, Cooper D, **Xu ML**, Girardi M, Foss F. Allogeneic stem cell transplant for CD8+ cytotoxic and gamma-delta cutaneous T-cell lymphomas. Poster presentation at Society for Investigative Dermatology, Albuquerque, NM.

2014 Fraser J, Subtil A, Seropian S, Cooper D, **Xu ML**, Foss F. Cytotoxic and gamma-delta subtypes of peripheral T-cell lymphoma: a single center experience. Poster presentation at T-cell Lymphoma Forum, San Francisco, CA.

2013 Ho C, Yao X, Tian L, Li F, Podoltsev N, **Xu ML**. Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability. Poster at USCAP, Baltimore, MD.

2013 Chen BJ, Ouyang J, **Xu ML**, Yu H, Fletcher CDM, Sun H, Shipp MA, Rodig SJ. Expression of the immunosuppressive molecules PD-L1 and Galectin-1 by EBV positive lymphoproliferative disorders: novel candidates for targeted immunotherapy. Oral presentation at USCAP, Baltimore, MD.

2012 Alomari A, Hui P, **Xu ML**. Composite peripheral T-cell lymphoma, not otherwise specified and B-cell small lymphocytic lymphoma presenting with hemophagocytic lymphohistiocytosis. Poster presentation at CAP, San Diego, CA.

2012 Chen BJ, **Xu ML**, Rodig, S. Expression of Galectin-1 by EBV positive lymphoproliferative disorders. Poster presentation at USCAP, Vancouver, Canada.

2008 **Xu ML**, Martel M, Schwartz P, Hui P. HER-2/neu receptor gene amplification and protein expression in endometrial cancers: A comprehensive tissue microarray study. Poster presentation at USCAP, Denver, CO.

2008 **Xu ML**, Bin Y, Carcangiu ML, Hui P. Epithelioid trophoblastic tumor: Comparative genomic hybridization and diagnostic DNA genotyping. Poster presentation at USCAP, Denver, CO.

2005 **Xu ML**, Chiang M, Lee W, Pear WS, Aster JC. Identification of a C-terminal negative regulatory sequence in NOTCH1 that influences signal strength and leukemogenic activity. Blood vol 106 no. 11 November 16, 2005. Oral presentation at American Society of Hematology, Atlanta, GA.

2005 Sanchez-Irizarry C, Malecki M, Lee W, **Xu ML**, Blacklow SC, Aster JC. Functional analysis of leukemia-associated mutations involving the heterodimerization domain of NOTCH1. Blood vol 106 no. 11 November 16, 2005. Poster presentation at American Society of Hematology, Atlanta, GA.

2005 Chiang MY, Hong S, Shestova O, Lee W, **Xu ML**, Pear WS, Aster JC. Synergistic induction of T cell acute lymphoblastic leukemia by functionally distinct mutations in NOTCH1. Blood vol 106 no. 11 November 16, 2005. Poster presentation at American Society of Hematology, Atlanta, GA.

1996 Mega MS, **Xu LQ**, Karaka TJ, et al. Standardization of MRI volumetric studies: Hippocampal atrophy predates clinical symptoms in individuals at risk for Alzheimer’s disease. Neurology, no.2 suppl vol 46 February 1996. Poster presentation at American Academy of Neurology, San Francisco, CA.

1996 Thompson PM, Mega MS, Moussai J, Zohoori S, **Xu LQ**, Goldkorn A, Khan AA, Coryell J, Small GW, Cummings J, Toga AW. 3D probabilistic atlas and average surface representation of the Alzheimer’s brain, with local variability and probability maps of ventricles and deep cortex. Poster presentation at Society for Neuroscience, Washington, DC.

**Regional**

2019 Schwaber E, Farhan M, D’Souza S, **Xu ML**, Nguyen K. Two for the price of one: simultaneous discovery of chronic myelomonocytic leukemia and multiple myeloma. Poster presentation at American College of Physicians (ACP) Meeting; Hartford, CT.

2019 Harigopal M, Yoon E, Patel N, **Xu M**, Manrai P. Incorporating flipped classroom in graduate medical education for pathology residents using a team-based approach. Poster presentation at Annual Yale Medical Education Fellowship Day, New Haven, CT.

2009 **Xu ML**, Abu-Alfa A, High WA, Kuo P, Cowper SE. Clinicopathological, microanalytical and physiological corroboration of NSF disease activity using inductively coupled plasma mass spectrometry and FDG-PET/CT imaging. Poster presentation at Annual Scientific Symposium on NSF and GBCA, New Haven, CT.

**Professional Service**

Journal Service

2021 - present Associate Editor, Frontiers in Oncology, Hematologic Malignancies Section

2021 - present Editor, Journal of Clinical and Translational Pathology

2020 - 2021 Editor, Frontiers in Oncology, special issue: Novel diagnostic tools and biomarkers in hematologic malignancies

Ad Hoc Reviewer

Archives of Pathology and Laboratory Medicine, Blood, Pediatric and Developmental Pathology, Journal of Clinical Pathology, Hematology Reports, European Journal of Haematology, Case Reports in Hematology, Clinical Case Reports, Neoplasia, FASEB, Blood Advances, Nature Communications, Haematologica, Journal of OncoTargets and Therapy, Journal of ImmunoTherapy of Cancer

**Service for Professional Organizations:**

2021 - present Leader, Hodgkin Lymphoma & Histiocytic/dendritic cell neoplasms disease group; International WHO sequencing project (Atlas of Blood Cancers - Genomics)

2021 - present Alliance for Clinical Trials in Oncology Circulating Tumor DNA Working Group

2020 - present Head of Hematopathology in Connecticut Society

2020 - present CAP Hematology/Clinical Microscopy Committee

 *CAP TODAY* Q&A Responder for Hematology Questions

2020 - present Central Pathology Review Committee for CALGB 50801

2020 - 2022 ASCP Hematopathology Abstract Reviewer

2019 - present Pathology member of Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group B)

2019 - present Faculty Consultant for Kilimanjaro Christian Medical Center Telepathology: providing pro bono diagnostic consults for a large hospital in Tanzania

2019 - present Pure Marrow Advisory Board

2018 - present Seattle Genetics Pathology Advisory Board

2016 - present Seattle Genetics Non-Hodgkin Lymphoma Diagnostic Advisory Board

 2011 - present Society for Hematopathology

2016- - 2016 - 2019 ASCP RISE/FISHE examination subcommittee

 2007 - presentUnited States & Canadian Academy of Pathology

 Ambassador (2016-2019)

 Social Media Committee (2016-2017)

 USCAP Abstract Reviewer (2016-2019)

**Yale University Service:**

***University Committees***

2023 - present Thesis committee member for Archibald Enninful in Biomedical Engineering

2023 - present Thesis committee member for Negin Farzad in Biomedical Engineering

2021 - present DeLuca Center Pilot Grant Review Committee

***Medical School Committees & Other Service***

2018 - present YSM Genes & Development: Course Director for Hematopathology/Malignant Hematology and Malignant Heme Content Leader

2018 - present Status of Women in Medicine:

* Speaker for Yale School of Medicine seminar

***Hospital and Departmental Committees***

2023 - present Director of Expert Consultation Practice, Yale Department of Pathology

2023 - present Pathology Research Pilot Grant Review Committee

2021 - present Residency Recruitment Committee

2021 - present Bone Marrow Biopsy Standard Operating Procedures Committee

2021 - present Chair of Search Committee, recruitment for Associate Professor of Hematopathology, Yale Pathology Department

2021 - present Search Committee, Director of Anatomic Pathology, Yale Pathology Department

2021 - present DeLuca Center Pilot Grant Review Committee

2021 - present Pathology Compensation Committee

2020 - present Search Committee, recruitment for senior scientist Joseph Madri Professorship

2020 - present Immunohistochemistry Laboratory Advisory Committee

2020 - 2021 Course Director for Hematopathology 101 yearlong course for Department of Internal Medicine and Hematology Division residents and fellows (monthly lectures)

2020 - present Management Team of Yale Department of Pathology

2019 - present Leukemia Clinical Practice Standardization Committee

2019 - 2020 Executive Team of Yale Department of Pathology

2019 - 2021 Search Committee, recruitment for Vice Chair of Molecular and Genomic Diagnostics, Department of Pathology and Laboratory Medicine

2015 - present Pathology Representative, NCCN Guidelines Institutional Review Committee for Acute Myeloid Leukemia, Chronic Lymphocytic Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma and Myeloproliferative Neoplasms

2017 - 2019 Search Committee, recruitment for Chief of Benign Hematology, Department of Internal Medicine, Section of Hematology

2017 - 2019 Search Committee, recruitment for Director of Lymphoma Program, Department of Internal Medicine, Section of Hematology

2017 - 2018 Chair of Search Committee, recruitment for Assistant Professor of Hematopathology, Yale Pathology Department

2016 - present Hematopathology ACGME Fellowship Program Evaluation Committee

2016 - 2018 Search Committee, Center for Aging recruitment for scientist in Cancer and Aging, Yale Pathology Department

2011 - 2014 Curriculum Committee, Yale Hematology/Oncology Fellowship: Hematopathology Rotation

**Bibliography:**

**Peer-Reviewed Original Manuscripts**

**(\* denotes last-author citations in which a student/resident is first author)**

1. Mega MS, Thompson PM, Cummings JL, Back CL, **Xu ML**, Zohoori S, Goldkorn A, Moussai J, Fairbanks L, Small GW, Toga AW. Sulcal variability in the Alzheimer’s brain: correlations with cognition. Neurology 1998; 50: 145-151.
2. Mega MS, Small GW, **Xu ML**, Felix J, Ercoli LM, Bookheimer SY, Goldberg RA. Hippocampal atrophy in persons with mild cognitive impairment. Psychosomatic Medicine 2002; 64: 487-92.
3. **Xu ML**, Chiang MY, Histen G, Shestova O, Roy M, Nam Y, Blacklow SC, Sacks DB, Pear WS, Aster JC. Identification of a conserved negative regulatory sequence that influences the leukemogenic activity of NOTCH1. Molecular Cellular Biology 2006; 26: 6261-71.
4. Malecki MJ, Sanchez-Irizarry C, Mitchell JL, Histen G, **Xu ML**, Aster JC, Blacklow SC. Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Molecular Cellular Biology 2006; 26: 4642-51.
5. Dickey CC, McCarley RW, **Xu ML**, Seidman LJ, Voglmaiera MM, Niznikiewicz MA, Connor E, Shenton ME. MRI abnormalities of the hippocampus and cavum septi pellucidi in females with schizotypal personality disorder. Schizophrenia Research 2007; 89: 49-58.
6. **Xu ML**, Bin Y, Carcangiu ML, Hui P. Epithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotyping. Modern Pathology 2009; 22: 232-8.
7. **Xu ML**, Martel M, Schwartz P, Hui P. HER-2/neu receptor gene status in endometrial carcinomas: A tissue microarray study. Histopathology 2010; 56: 269-73.
8. Varughese N, Duong A, Emre, S, **Xu ML**, Lee A. Venting the spleen. New England Journal of Medicine 2013; 369: 1357-63.
9. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, **Xu ML**, Yu H, Fletcher C, Freeman GJ, Shipp MA, Rodig SJ. PD-L1 Expression is characteristic of a subset of Aggressive B-cell lymphomas and virus-associated malignancies. Clinical Cancer Research 2013; 19: 3462-73.
10. Al-Omari A, Hui P, **Xu ML**. Composite peripheral T-cell lymphoma, not otherwise specified and B-cell small lymphocytic lymphoma presenting with hemophagocytic lymphohistiocytosis. International Journal of Surgical Pathology 2013; 21: 303-8. **\***
11. **Xu ML** and Cooper, D. Caught in transformation. Blood 2014; 124: 2749.
12. Ahmad AK, Hui P, Litkouhi B, Azodi M, Rutherford T, McCarthy S, **Xu ML**, Schwartz PE, Ratner E. Institutional review of primary non-Hodgkin lymphoma of the female genital tract: a 33-year experience. International Journal of Gynecological Cancer 2014; 24:1250-5.
13. Ho C, Yao X, Tian L, Li F, Podoltsev N, **Xu ML**. Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability. American Journal of Clinical Pathology 2014; 141: 62-71. **\***
14. **Xu M,** Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology 2015; 69(1): 155-158.
15. Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RS, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsu ED, Choi W, van Krieken H, Huh J, Ponzoni M, Ferreri A, Zhang S, Parsons BM, **Xu M**, Moller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros J, Young KH. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma—is it necessary? Oncotarget 2015; 6(16):13933-45.
16. Gibson JF, Kapur L, Sokhn J, **Xu M**, Foss FM. A fatal case of primary cutaneous gamma-delta T-cell lymphoma complicated by HLH and cardiac amyloidosis. Clin Case Rep. 2015; 3(1):34-8.
17. Munday WR, Kapur LH, **Xu M**, Zhang X. Russell body duodenitis with immunoglobulin kappa light chain restriction. World Journal of Gastrointestinal Endoscopy 2015; 7: 73-6.
18. Simmons NR, **Xu ML**, Tavassoli FA, Geisel J, Killelea B, Philpotts LE. A rare presentation of Rosai-Dorfman disease as a breast mass. Breast J 2016; 22(5):581-3.
19. Deng L, Xu-Monette ZY, Loghavi SN, Manyam GC, Xia Y, Visco C, Huh J, Zhang L, Zhai Q, Wang Y, Qiu L, Dybkaer K, Chiu A, Perry AM, Tzankov A, Rao H, Abramson J, Sohani AR, **Xu M**, Hsi ED, Zhu J, Ponzoni M, Wang S, Zhang M, Ferreri AJ, Parsons BM, Li Y, Piris MA, Medeiros LJ, Young KH. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: A report from the International PTL Consortium. Leukemia 2016; 30(2):361-72.
20. Stahl M, **Xu ML**, Steensma DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Annals of Hematology 2016; 95(7): 1197-200.
21. Onuoha C, Arshad J, Astle J, **Xu M**, Halene S. Novel developments in leukopenia and pancytopenia. Primary Care Clinics in Office Practice 2016; 43(4):559-573.
22. Gauthier AC, Nguyen A, Munday WR, **Xu ML**, Materin MA. Anterior chamber non-Hodgkin Lymphoma of the iris masquerading as uveitis-glaucoma-hyphema syndrome. Ocul Oncol Pathol 2016; 2(4): 230-233.
23. Kim TK, **Xu ML**, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K, Stahl M, Gore SD, Zeidan AM. Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. Annals of Hematology 2016; 95(11):1895-8.
24. Sharma P, Balasingham S, Stawiarski K, Rahmani M, Costantino A, Sharma P, **Xu M**, Masoud A.  Burkitt lymphoma as a lead point for jejunojejunal intussusception in a human immunodeficiency virus patient. Clin J Gastroenterol 2017; 10(4):342-350.
25. Zeidan AM, **Xu M**, Steensma DP. The importance of erythroblast enumeration in myeloid neoplasia. Ann Hematol 2017; 96(2):329-330.
26. Baraban EG, Hu S, Hui P, Podoltsev N, Cooper D, **Xu ML**. Tissue based chimerism analysis enhances detection of donor derived neoplasia in allogeneic stem cell transplant patients. Bone Marrow Transplantation 2017; 52(4):634-637. **\***
27. Astle JM, **Xu ML**, Friedman T, Brown E. Limitations of poor bone marrow aspirations (for an accurate diagnosis) despite the multi-modal analytical era: a longitudinal retrospective study. American Journal of Hematology 2017; 92(10):E600-E602.
28. Pelland K, Mathews S, Kamath A, Cohen P, Hudnall SD, Cotta CV, **Xu ML**. Dendritic cell markers and PD-L1 are expressed in Mediastinal Gray Zone Lymphoma. Appl Immunohistochem Mol Morphol 2017; 1541-2016. **\***
29. Bailur JK, Mehta S, Zhang L, Neparidze N, Parker T, Bar N, Anderson T, **Xu M**, Dhodapkar KM, Dhodapkar MV. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Adv 2017;1(25):2343-2347.
30. Romberg N, Le Coz C, Glauzy S, Schickel J, Trofa M, Nolan B, Paessler M, **Xu ML**, Lamber M, Lakhani SA, Khokha MK, Jyonouchi S, Heimall J, Takach P, Maglione PJ, Catanzaro J, Hsu I, Sullivan KE, Chunningham-Rundles C, Meffre E. Common variable immunodeficiency patients with autoimmune cytopenias display hyperplastic and inefficient germinal center responses. J Allergy Clin Immunol 2018; S0091-6749(18);30897-2.
31. Rahmani M, Halene S, **Xu ML**. Small cell variant of Intravascular Large B-cell Lymphoma: highlighting a potentially fatal and easily missed diagnosis. Biomed Research International 2018:9413015. **\***
32. Shallis RM, **Xu ML**, Podoltsev NA, Curtis SA, Considine BT, Khanna SR, Siddon AJ, Zeidan AM. Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice. Annals of Hematology 2018;97(12):2333-2343.
33. Shallis RM, **Xu ML**, Curtis SA, Medoff E, Mixon R, Folkers A, Zeidan AM. Conviction in the face of affliction: a case series of Jehovah’s witnesses with myeloid malignancies. Annals of Hematology 2018;97(11):2245-2248.
34. Song Y, Rongvaux A, Taylor A, Jiang T, Zhao J, Balasubramanian K, Bagale A, Terzi YK, Tebaldi T, Podoltsev N, **Xu M**, Neparidze N, Wong E, Torres R, Bruscia E, Kluger Y, Manz MG, Flavell R, Halene S. A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. Nature Communications 2019;10(1):366.
35. Goldfinger M, **Xu ML**, Bertino JR, Cooper DL. Checking in on lenalidomide in Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leukemia 2019; S2152-2650(18):31447-2
36. Shallis R, Gleeson S, Azar M, Malinis M, **Xu ML**, Seropian S, Gowda L, Zeidan A. Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications and considerations. Leukemia & Lymphoma 2019 Apr 3; 1042-8194.
37. Patel S, Ho C, Sadigh S, Bagg A, Geyer J, **Xu M**, Mason E, Seegmiller A, Morgan E, Steensma D, Winer E, Hasserjian R, Weinberg O. Clinicopathologic and genetic characterization of non-leukemic NPM1-mutated myeloid neoplasms. Blood Adv 2019;3(9):1540-1545.
38. Yuan J, Li S, Liu X, Su RJ, Chen M, Wu X, Zheng G, Smith LM, Wang L, Li Y, Liu C, Zhou J, Shen Q, Zhang L, Wang E, **Xu ML**, Pan Z. Mantle cell lymphoma with mantle zone growth pattern. Am J Clin Pathol 2019;152(2):132-145.
39. Chen PH, Yang Y, O’Malley DP, **Xu ML**. Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx. Ann Diagn Pathol. 2019;41:129-135. **\***
40. Gong Z, **Xu ML**, Chen M, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S. Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia. Am J Hematol. 2019;94(10):E256-E259.
41. Wang JD, Katz SG, Morgan EA, Yang DT, Pan X, **Xu ML**. Pro-apoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. Hum Pathol. 2019;S0046-8177(19)30141-8. **\***
42. Maracaja DLV, Puthenpura V, Pels SG, O'Malley D, Sklar J, Finberg K, **Xu ML**. EBV-Positive Primary Large B-cell Lymphoma: the role of immunohistochemistry and XPO1 in the diagnosis of mediastinal lymphomas. AIMM. 2019;28(10):725-730. **\***
43. Nair S, Bar N, **Xu ML**, Dhodapkar M, Mistry PK. Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. Molecular Genetics and Metabolism. 2020;129(4):286-291.
44. Shallis RM, Patel TH, Podoltsev NA, **Xu ML**, Azar MM, Gore SD. Disseminated, yet dissembled: rare infections behind the veil of classical hairy cell leukemia. Leukemia Research. 2020;90:106315.
45. Toki M, Kumar D, Ahmed F, Rimm D, **Xu ML**. Benign lymph node microenvironment is associated with response to immunotherapy. Precision Clinical Med 2020;3(1):44-53. **\***
46. Kuhny M, Forbes, L, Cakan E, Vega-Loza A, Kostiuk V, Dinesh R, Glauzy S, Stray-Pedersen A, Pezzi A, Hanson IC, Vargas-Hernandez A, **Xu M**, Akdemir Z, Jhanjiani S, Muzny D, Gibbs R, Lupski J, Chinn I, Schatz D, Orange J, Meffre E. Disease associated CTNNBL1 mutation impairs somatic hypermutation by decreasing AID binding and nuclear localization. Journal of Clinical Investigation. 2020;130(8):4411-4422.
47. Bar N, Costa F, Das R, Duffy A, Samur M, McCahren S, Gettinger S, Neparidze N, Parker T, Bajpai R, Zhang L, **Xu ML**, Anderson T, Cho H, Raval A, Shanmugam M, Dhodapkar K, Dhodapkar M. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human lung cancer and myeloma. Journal of Clinical Investigation. 2020;18;5(12):e129353.
48. Hedge M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, **Xu ML**, Gerken C, Kaira M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed N. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nature Communications. 2020;11(1):3549.
49. Panse G, Subtil A, McNiff J, Glusac E, Ko C, Galan A, Myung P, **Xu ML**. Cutaneous involvement in plasma cell myeloma. AJCP. 2020;155(1):106-116.
50. **Xu ML**, Gabali A, Hsu ED, Fedoriw Y, Vij K, Salama ME, Ramchandren R, O’Malley D, Wick MR, Battistella M, Gru AA. Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. Am J Surg Pathol. 2020; 44(2):e1-e14.
51. Verma R, Branagan A, **Xu ML**, Flavell RA, Dhodapkar K, Dhodapkar M. Role of MBD3-SOX2 axis in residual myeloma following pomalidomide. Leukemia 2020;35(11):3319-3323.
52. Lin N, Vargas-Pinto S, Gisriel S, **Xu M**, Gibson CE. Diffuse large B-cell and follicular lymphoma presenting as a slowly growing compressive goiter: a case report and literature review. Int J Surg Case Rep. 2020;72:615-619.
53. Gu S, Pan Z, **Xu ML**. Thinking outside the cavity: effusion lymphoma primary to bone marrow. Clinical Case Reports. 2021;9(5):e04100. **\***
54. Weinberg OK, Chisholm KM, Ok CY, Fedoriw Y, Grzywacz B, Kurzer JH, Mason EF, Moster KA, Bhattacharya S, **Xu ML**, Babu D, Foukar K, Tam W, Bagg A, Orazi A, George TI, Wang W, Wang SA, Arber D, Hasserjian RP. Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Modern Pathology. 2021;34(7):1358-1366.
55. Song Y, Shan L, Gbyll R, Liu W, Strowig T, Patel A, Fu X, Wang X, **Xu ML**, Gao Y, Qin A, Bruscia EM, Tebaldi T, Biancon G, Mamillapalli P, Urbonas D, Eynon E, Gonzaliz DG, Krause DS, Alderman J, Halene S, Flavell RA. Combined liver-cytokine humanization comes to the rescue of circulating human red blood cells. Science. 2021;371(6533):1019-1025.
56. Gru AA, Bacchi CE, Pulitzer M, Baghat G, Kempf W, Robson A, Plaza JA, Pincus L, Raghavan S, **Xu ML**, Subtil A, Battistella M. Secondary skin involvement in classic Hodgkin lymphoma: results of an international collaborative cutaneous lymphoma working group study of 25 patients.” Journal of Cutaneous Pathology. 2021;48(11):1367-1378.
57. Katz SG, Edappallath S, **Xu ML**. IRF8 is a reliable monoblast marker for acute monocytic leukemias. April 2021 Am Journal Surg Pathology. 2021;45(10):1391-1398.
58. Li P, Yuan J, Ahmed FS, McHenry A, Fu K, Yu G, Cheng H, **Xu ML**, Rimm DL, Pan Z. High counts of CD68+ and CD163+ macrophages in mantle cell lymphoma are associated with inferior prognosis. Frontiers in Oncology. 2021;11:701492.
59. Gershkovich P, Gibson J, Gilshannon M, Kowalski D, Levi A, Nguyen D, Rimm DL, **Xu ML**, Sinard J. Measuring faculty effort: a quantitative approach that aligns personal and institutional goals in pathology at Yale. Academic Pathology. 2021;8:23742895211047985.
60. Gu S, Pan Z, **Xu ML**. Thinking outside the cavity: effusion lymphoma primary to bone marrow. Clinical Case Reports. 2021;9(5):e04100. **\***
61. Korn LL, **Xu ML**, Brunet C. A multidisciplinary approach required. The Rheumatologist. 2022 [Accepted].
62. Hrones M, Harigopal M, **Xu ML**, Abi-Raad R. Breast-implant associated anaplastic large-cell lymphoma: a series of two case reports diagnosed by cytopathology. Diagnostic cytopathology. 2022; PMID 36066320.
63. Irshaid L, Bleiberg J, Weinberger E, Garritano J, Shallis RM, Patsenker J, Lindenbaum O, Kluger Y, Katz SG, **Xu ML**. Histopathologic and machine deep learning criteria to predict lymphoma transformation in bone marrow biopsies. Archives of Pathology & Lab Med. 2022;146(2):182-183. **\***
64. Johnson J, McGuone D, **Xu ML**, Jane-Wit D, Mitchell RN, Libby P, Pober J. COVID Coronary vascular thrombosis: correlation with neutrophil but not endothelial activation. American Journal of Pathology. 2022;192(1):112-120.
65. Li P, Biancon G, Patel T, Pan Z, Kothari S, Halene S, Prebet T, **Xu ML**. Comprehensive clinicopathologic and molecular analysis of mast cell leukemia with associated hematologic neoplasm. Frontiers in Oncology. 2021;11:730503. **\***
66. Matsumoto N, Yuan J, Wang J, Shen Q, Chen X, Kim Y, Zuppan C, Chang C, Cui W, Chen D, Shi M, Gisriel S, Chen M, **Xu ML**, and Pan Z. Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature. Modern Pathology. 2022; PMID: 35105959.
67. McQuaid D, Panse G, Wang WL, Pinkus GS, Katz SG, **Xu ML**. Global assessment of IRF8 as a novel cancer biomarker. Human Pathology. 2022: S0046-8177(22)00014-4. **\***
68. Jawad M, Afkhami M, Ding Y, Zhang X, Li P, Young K, **Xu ML**, Cui W, Zhao Y, Halene S, Al-Kali A, Viswanatha D, Chen D, He R, Zheng G. DNMT3A R882 mutations confer unique clinicopathologic features in MDS including a high risk of AML transformation. Front Oncol. 2022;28(12):849376.
69. Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Sethi T, McHenry A, Hauser RG, Paulson N, His ED, Young KH, **Xu ML**, Pan Z. Human herpesvirus 8- negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology. 2022; PMID:35562413.
70. McQuaid D, Katz SG, **Xu ML**. IRF8 as a novel marker to differentiate between CD30-positive large cell lymphomas. AJCP. 2022; PMID:35460405. **\***
71. Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, **Xu ML**, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia 2022; PMID 36335264.
72. Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, **Xu ML**, Foss F. Peripheral blood involvement at staging in patients with aggressive peripheral T-cell lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2022 Apr 22:S2152-2650(22)000134-3.
73. **Xu ML**, Katz SG. Response to Letter to the Editor: IRF8 is a reliable monoblast marker for acute monocytic leukemias but does not discriminate between monoblasts and plasmacytoid dendritic cells. AJSP. 2022; PMID 36040049.
74. Bewersdorf J, Buckstein R, Sekeres M, Steensma M, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett J, Borate U, Brunner A, Carraway H, Churpek J, Daver N, Della Porta M, DeZern A, Efficace F, Fenaux P, Figueroa M, Greenberg P, Griffiths E, Halene S, Hasserjian R, Hourigan C, Kim N, Kim T, Komrokji R, Kutchroo V, List A, Little R, Majeti R, Nazha A, Nimer S, Starczynowski D, Xie Z, **Xu ML**, Savona M, Wei A, Abdel-Wahab O, Santini V, Zeidan A. Finding consistency in international classifications of myeloid neoplasms: a perspective on behalf of the first International Workshop on Myelodysplastic Syndromes. Leukemia. 2022; PMID 36266326.
75. Deng Y, Bartosovic M, Ma S, Zhang D, Kukanja P, Xiao Y, Su G, Liu Y, Qin X, Rosoklija G, Dwork A, Craft J, Leong K, Mann J, **Xu ML**, Halene S, Castelo-Branco G, Fan R. Spatial profiling of chromatin accessibility in mouse and human tissues. Nature 2022; PMID 35978191.
76. Patnaik MM, Zeidan A, Padron E, Platzbecker U, Sallman D, DeZern AE, Bejar R, Sekeres M, Taylor J, Little R, Bewersdorf J, Kim T, Kim N, Della Porta M, Stahl M, Steensma D, **Xu ML**, Odenike O, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Bennett J. Updated Classification Schema for Myelodysplastic/Myeloproliferative Overlap Neoplasms. Leukemia. 2022 [Accepted].
77. Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, **Xu ML**, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia. 2022; PMID 36266326.
78. Gru AA, Lim M, Dogan A, Horwitz S, Delabi J, Fu K, Peker D, Reddy V, **Xu ML**, Vij K, Slack G, Miranda RN, Jagadeesh D, Lisano J, Hsu ED, Torlavic E. Best practices in CD30 testing, interpretation and reporting, expert panel consensus. Archives of Path Lab Med. 2022 Apr 26 [In Press].
79. Mandell JD, Fisk N, Cyrenne E, **Xu ML**, Cannatoar VL, Townsend JP. Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1-RUNX1T1-fusion-positive acute myeloid leukemia. Leukemia. 2022 [Accepted].
80. Young KHH, Li Y, Xu-Monette ZY, Abramson JS, Sohani A, Bhagat G, Tzankov A, Visco C, Zhang S, Dybkaer K, Pan Z, **Xu ML**, Tam W, Zu Y, Hsi ED, Hagemeister FB, Go H, van Krieken J, Winter JN, Ponzoni M, Ferreri AJM, Moller MB, Piris MA, Wang Y, Zhang M. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential. Blood Adv. 2022 [Accepted].
81. Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Litter RF, Bewesdorf JP, Kim TK, Kim N, Hougan CS, Dela Porta MG, Stahl M, Steensma D, **Xu ML**, Odenike O, Carraway H, Komroji R, Loghani S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia. 2022; 36(12):2934-2938.
82. Stahl M, Abdel-Wahab O, Wei AH, Savona MR, **Xu ML**, Xie Z, Taylor J, Starczynowski DT, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore SD, List AF, Kuchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in MDS: A TOP 10 priority list from the first international workshop in MDS (iwMDS). Blood Adv. 2022; PMID 36260702.
83. Fan R, Baker C, Glusac EJ, **Xu ML**, Gru AA, Cohen JM. Acute Epstein-Barr virus infection resembling cutaneous T-cell lymphoma. J Cutan Pathol. 2022; PMID 36349388.
84. Liu Y, DiStasio M, u G, Asashima H, Enninful A, Qin X, Deng Y, BordignonP, Cassano M, Tomayko M, **Xu ML**, Halene S, Craft JE, Hafler D, Fan R. High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq. Nature Biotechnology; Accepted.
85. Hu Z, Medeiros LJ, **Xu M**, Yuan J, Peker D, Shao L, Tang Z, Mai B, Thakral B, Rios A, Hu S, Wang W. T-cell Prolymphocytic Leukemia with t(X;14)(q28;q11.2): a clinicopathologic study of 15 cases. AJCP. 2023. Mar 8. [PMID 36883805].
86. Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton MR, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, **Xu ML**, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos BM, Karmali R, Oh TS, Vose JM, Nutsch HR, Rubinstein PG, Chaudhry A, Olszewski AJ. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Adv. 2023. May 12 [PMID 37171397].
87. Tang H, Panse G, Braddock D, Perincheri S, **Xu ML**, McNiff JM. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression. J Cutan Pathol. 2023;50(7):595-600. [PMID 37082914].
88. Tang H, Matsumoto N, Foss F, **Xu M**, Ahmed A. Clinicopathologic features of cutaneous T-cell lymphomas with extracutaneous metastasis. Clin Lymphoma Myeloma Leuk. 2023 Aug 14 [PMID: 37659965].
89. Tang H, Matsumoto N, Foss F, **Xu M**, Ahmed A. IRF8 in conjunction with CD123 and CD20 to distinguish lupus erythematosus panniculitis from subcutaneous panniculitis-like T-cell lymphoma. Am J Surg Pathol. 2023 Sep 28 [PMID: 37767989].

**Chapters, Books, Reviews**

1. **Xu M**, Huang A. “Chapter 4: Pathology.” *First Aid for the Match*, 5th ed. Edited by Le T, Bhushan V, Shenvi C. McGraw-Hill Medical, 2010.
2. McClaskey J, **Xu M**, Snyder EL, Tormey CA. Clinical trials for pathogen reduction in transfusion medicine: a review. Transfusion Apheresis Sci 2009;41(3):217-25.
3. **Xu M**, Fedoriw Y. Lymphoma microenvironment and immunotherapy. Surgical Pathology Clinics 2016; 9(1):93-100.
4. **Xu ML,** O’Malley D. Lymph node stromal and vascular proliferations. Seminars in Diagnostic Pathology 2018; 35(1):67-75.
5. Kumar D, **Xu ML**. Microenvironment cell contribution to lymphoma immunity. Frontiers in Oncology 2018; 27(8):288. **\***
6. Pan Z, **Xu ML**. Histiocytic and Dendritic Cell Neoplasms. Surg Pathol Clin. 2019;12(3):805-829.
7. **Xu ML**. Hematopathology. Surg Pathol Clin. 2019;12(3):xi.
8. Irshaid L, **Xu ML**. ALCL by any other name: the many facets of anaplastic large cell lymphoma. Pathology. Pathology 2020;52(1):100-110. **\***
9. Siddon A, **Xu ML**. “Chapter 7: Immunophenotyping of normal and neoplastic immature T cells” *Clinical flow cytometry: approaches, principles and applications.* Edited by Jason Kurzer and Olga Weinberg. Nova Science Publishers, 2019.
10. Irshaid L, **Xu ML**. Major subtypes of mature T- and NK-cell neoplasms. Practical lymph node and bone marrow pathology. 2020;8:175-188. **\***
11. Pan Z, **Xu ML**. T-Cell and NK-Cell Lymphomas in the Lung. Seminars in Diagnostic Pathology. 2020;37(6):273-282.
12. Shallis R, Gale R, Lazarus HM, Roberts KB, **Xu ML**, Seropian S, Gore S, Podoltsev NA. Myeloid sarcoma, chloroma, extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved. Blood Reviews. 2020;47:100773.
13. Verma A, **Xu ML**. Emerging immunohistochemical biomarkers for myeloid neoplasms. Archives of Pathology & Lab Med. 2022 May 9 [In Press]. **\***
14. Gisriel SD, **Xu ML**. Approach to Lymphoproliferative Disorders of the GI tract. Interpretation & Reporting of Gastrointestinal Biopsies. Wolters Kluwer. 2022 [Accepted as book chapter]. **\***
15. Shallis R, **Xu ML**, Zeidan A, Halene S. “Myelodysplastic Syndrome.” *Cancer. 12th ed*. Wolters Kluwer. 2022.
16. **Xu ML**, Hasserjian RP. Updates in classification of myelodysplastic syndrome. The Cancer Journal. 2023. May-Jun [PMID 37195767]
17. Bewersdorf JP, Xie Z, Bejar R, Borate U, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, Porta MGD, DeZern AE, Fenaux P, Figueroa ME, Gore SD, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim TK, Komrokji R, Kuchroo VK, List AF, Loghavi S, Majeti R, Odenike O, Patnaik MM, Platzbecker U, Roboz GJ, Sallman DA, Santini V, Sanz G, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, **Xu ML**, Savona MR, Wei AH, Zeidan AM. Curent landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) of the International Consortium for MDS (icMDS). Blood Rev. 2023. Mar 11 [PMID 36934059].
18. Stahl M, Bewersdorf JP, Xie Z, Porta MGD, Komrokji R, **Xu ML**, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, Sekeres MA, Sanz G, Sallman DA, Roboz GJ, Platzbecker U, Patnaik MM, Padron E, Odenike O, Nimer SD, Nazha A, Majeti R, Loghavi S, Little RF, List AF, Kim TK, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Gore SD, Greenberg P, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Daver NG, Churpek JE, Carraway HE, Buckstein R, Brunner AM, Boultwood J, Borate U, Bejar R, Bennett JM, Wei AH, Santini V, Savona MR, Zeidan AM. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev. 2023 Aug 19 [PMID 37704469].